Jared Gollob, Chief Medical Officer at Kymera Therapeutics, Inc. (KYMR), sold 92,274 shares at $35.39 ($3.3M) on 2024-02-09, disclosed to the SEC on 2024-02-09.
Scheduled sale ($3.3M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.39 | 38,739 | $1.4M | 41.8% |
| 2 | $35.39 | 38,739 | $1.4M | 41.8% |
| 3 | $36.09 | 7,398 | $267K | 8.2% |
| 4 | $36.09 | 7,398 | $267K | 8.2% |
| Total | $35.50 avg | 92,274 | $3.3M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-15 | $7.3M | — | Filing → |
| KYMR | SELL | 2025-10-14 | $187K | — | Filing → |
| KYMR | SELL | 2025-03-03 | $317K | — | Filing → |